MONDAY, April 11, 2022 (HealthDay News) — Regular users of phosphodiesterase type 5 inhibitors (PDE5Is) for erectile dysfunction may be at an increased risk for adverse ocular events, according to a study published online April 7 Is. JAMA Ophthalmology,
Mahayar Etminen, Pharm.D., from the University of British Columbia in Vancouver, Canada, and colleagues quantified the risk associated with the use of serous retinal detachment (SRD), retinal vascular occlusion (RVO), and ischemic optic neuropathy (ION). . of PDE5Is. The analysis included data from 213,033 men who received PDE5Is (sildenafil, tadalafil, vardenafil, and avanafil) from 2006 to 2020, while the case-control analysis included a total of 1,146 cases of SRD (278), RVO (628), and ION. were. 240) and 4,584 controls.
The researchers found that patients with SRD, RVO and ION were more likely to have high blood pressure, diabetes, coronary artery disease and sleep apnea. For the combination of any of the three outcomes, the incidence rate ratio (IRR) was 1.85 (incidence, 15.5 cases per 10,000 person-years). For the three individual outcomes, the adjusted IRRs were 2.58 (incidence, 3.8 cases per 10,000 person-years), 1.44 (incidence, 8.5 cases per 10,000 person-years) for RVO and 2.02 (incidence, 3.2 cases per 10,000 person-years). . -Year) for ION.
“Regular users of PDE5i should be aware of ocular adverse events associated with these drugs and alert their physicians if they experience any visual deficits,” the authors write.
One author disclosed financial ties to the pharmaceutical industry.
Abstract/full text (subscription or payment may be required)
Editorial (subscription or payment may be required)